The Corbevax is the country’s first RBD protein subunit vaccine, which aims to protect against COVID-19. Currently it is used under COVID-19 immunization programme to immunise kids between the ages of 12 to 14 years.
On June 4, the Drugs Controller General of India (DCGI) approved Corbevax as a precautionary dose for adults, who have successfully taken first two doses of the COVID-19 vaccine. It works as a booster dose for both Covaxin and Covishield. It can be taken after 6 months, or 26 weeks post the second dose of either of the two vaccines by anyone above the age of 18 years.
In its July 20 meeting, the COVID-19 Working Group (CWG) reviewed data from the double-blind randomized phase-3 clinical study that assessed the immunogenicity and safety of a booster dose of the Corbevax vaccine when given to COVID-19-negative adult volunteers between the ages of 18 and 80 who had previously received two doses of either Covishield or Covaxin.
On the Co-WIN portal, all essential adjustments are being made in relation to the delivery of the precautionary dosage of the Corbevax vaccination.
